Health
Ardelyx Receives New Patent for Tenapanor
New patent covers IBSRELA® and XPHOZAH® and expires in 2042WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26
About this update from Ardelyx, Inc.
[{"type":"image","alt":"Ardelyx, Inc.","displaySize":"","headline":null,"caption":"Ardelyx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MgPvxPnNoevfPj4GVpeYhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e","width":300,"height":69}},"lazy":false},{"type":"text","content":"New patent covers IBSRELA® and XPHOZAH® and expires in 2042","length":59,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for both products.","length":791,"tagName":"p"},{"type":"text","content":"“We are pleased to have been granted this patent for IBSRELA and XPHOZAH, which expires in fall of 2042,” said Mike Raab, president and chief executive officer of Ardelyx. “This is an important step in extending protections for our portfolio of first-in-class medicines in therapeutic areas where there continues to be significant unmet patient need. We are committed to executing a comprehensive intellectual property strategy that enables us to continue driving meaningful impacts for patients and creating lasting value for our shareholders.”","length":545,"tagName":"p"},{"type":"text","content":"The expiration date of November 26, 2042 for this patent is an update from information previously communicated by the Company, and reflects a Patent Term Adjustment resulting from USPTO delays.","length":193,"tagName":"p"},{"type":"text","content":"About IBSRELA® (tenapanor)IBSRELA (ten...